(Q40443624)

English

H1:IC31 vaccination is safe and induces long-lived TNF-α(+)IL-2(+)CD4 T cell responses in M. tuberculosis infected and uninfected adolescents: A randomized trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

20 September 2017

H1:IC31 vaccination is safe and induces long-lived TNF-α(+)IL-2(+)CD4 T cell responses in M. tuberculosis infected and uninfected adolescents: A randomized trial (English)

1 reference

Europe PubMed Central

20 September 2017

0 references

0 references

Mycobacterium tuberculosis

0 references

object named as

Helen Mearns

1

0 references

Benjamin M Kagina

object named as

Benjamin M Kagina

3

0 references

object named as

Peter Andersen

14

0 references

13

object named as

Mark Hatherill

1 reference

Europe PubMed Central

20 September 2017

Willem Albert Hanekom

8

object named as

Willem A Hanekom

1 reference

Europe PubMed Central

20 September 2017

Thomas J Scriba

15

object named as

Thomas J Scriba

1 reference

Europe PubMed Central

20 September 2017

author name string

Hennie D Geldenhuys

2

1 reference

Europe PubMed Central

20 September 2017

Munyaradzi Musvosvi

4

1 reference

Europe PubMed Central

20 September 2017

Francesca Little

5

1 reference

Europe PubMed Central

20 September 2017

Frances Ratangee

6

1 reference

Europe PubMed Central

20 September 2017

Hassan Mahomed

7

1 reference

Europe PubMed Central

20 September 2017

Søren T Hoff

9

1 reference

Europe PubMed Central

20 September 2017

Morten Ruhwald

10

1 reference

Europe PubMed Central

20 September 2017

Ingrid Kromann

11

1 reference

Europe PubMed Central

20 September 2017

Peter Bang

12

1 reference

Europe PubMed Central

20 September 2017

THYB04 study group

16

1 reference

Europe PubMed Central

20 September 2017

language of work or name

0 references

publication date

17 November 2016

1 reference

Europe PubMed Central

20 September 2017

1 reference

Europe PubMed Central

20 September 2017

35

1 reference

Europe PubMed Central

20 September 2017

1

1 reference

Europe PubMed Central

20 September 2017

132-141

1 reference

Europe PubMed Central

20 September 2017

TB vaccine development: where are we and why is it so difficult?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.023

7 January 2021

Vaccines for TB: Lessons from the Past Translating into Future Potentials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.023

7 January 2021

Tuberculosis in children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.023

7 January 2021

Innovative clinical trial designs to rationalize TB vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.023

7 January 2021

TB incidence in an adolescent cohort in South Africa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.023

7 January 2021

Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.023

7 January 2021

Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.023

7 January 2021

Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.023

7 January 2021

First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.023

7 January 2021

Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.023

7 January 2021

Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.023

7 January 2021

Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.023

7 January 2021

Safety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.023

7 January 2021

Qualification of a whole blood intracellular cytokine staining assay to measure mycobacteria-specific CD4 and CD8 T cell immunity by flow cytometry

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.023

7 January 2021

Novel application of a whole blood intracellular cytokine detection assay to quantitate specific T-cell frequency in field studies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.023

7 January 2021

SPICE: exploration and analysis of post-cytometric complex multivariate datasets

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.023

7 January 2021

The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.023

7 January 2021

The dynamics of QuantiFERON-TB gold in-tube conversion and reversion in a cohort of South African adolescents

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.023

7 January 2021

Prospects for Tuberculosis Elimination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.023

7 January 2021

T-cell quality in memory and protection: implications for vaccine design

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.023

7 January 2021

Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.023

7 January 2021

Control of chronic mycobacterium tuberculosis infection by CD4 KLRG1- IL-2-secreting central memory cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.023

7 January 2021

High-frequency vaccine-induced CD8⁺ T cells specific for an epitope naturally processed during infection with Mycobacterium tuberculosis do not confer protection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.023

7 January 2021

ESAT-6 (EsxA) and TB10.4 (EsxH) based vaccines for pre- and post-exposure tuberculosis vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.023

7 January 2021

Identifiers

10.1016/J.VACCINE.2016.11.023

1 reference

Europe PubMed Central

20 September 2017

1 reference

Europe PubMed Central

20 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40443624&oldid=1898036201"